ICG-124 by ICell Gene Therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

ICG-124 is under clinical development by iCell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).

Therapeutic HPV Vaccine Effective in Reducing Precancerous Cervical Lesions

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from a small

January 25, 2025

94% Of NY Cannabis Retailers Oppose Loosening 1,000-Foot Buffer Zone Between Legal Shops – Is The Market At Risk?

94% Of NY Cannabis Retailers Oppose Loosening 1,000-Foot Buffer Zone Between Legal Shops – Is The Market At Risk? A recent survey by the New

February 14, 2025

General Catalyst raises $8 billion, with $750 million for health care bets

The venture capital giant General Catalyst has raised $8 billion in fresh capital, with $750 million set aside for health care investments as its acquisition

October 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.